"Understanding how weight changes, side effects, and income relate to treatment discontinuation and reinitiation can inform clinical and policy strategies to ensure equitable access to GLP-1 RAs for patients who need them." "Improved understanding of the factors related to discontinuation and reinitiation of GLP-1RAs is essential for personalizing treatment to each patient's unique health needs and circumstances, said Ty J
Clinical studies have shown that patients using tirzepatide achieved significant weight loss compared to those using a placebo
Patients with prior neurodegenerative or cerebrovascular conditions were excluded from the analysis
doubling the next dose is discouraged to avoid paresthesia and confusion
Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, and Boyd AE, 3rd
Following treatment of HuOCSCs with the ferroptosis agonist erastin combined with anisomycin, the growth inhibition rate over time was significantly higher than that of the cells in the anisomycin alone and erastin alone groups (Figure 1A)
